ezn3042
Nucleic acidexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01186328)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
BIRC5 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ezn3042
- ezn 3042
- ezn-3042
- ezn-3042
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01186328 | Phase 1 | Aug 1, 2010 | Enzon, New York University, University of Southern California |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enzon | For profit | 1 | 0 | 1 | 2010 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2010 |
3 organizations
Page 1 / 1